» Articles » PMID: 10805796

Chromosomal Breakage-fusion-bridge Events Cause Genetic Intratumor Heterogeneity

Overview
Specialty Science
Date 2000 May 11
PMID 10805796
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

It has long been known that rearrangements of chromosomes through breakage-fusion-bridge (BFB) cycles may cause variability of phenotypic and genetic traits within a cell population. Because intercellular heterogeneity is often found in neoplastic tissues, we investigated the occurrence of BFB events in human solid tumors. Evidence of frequent BFB events was found in malignancies that showed unspecific chromosome aberrations, including ring chromosomes, dicentric chromosomes, and telomeric associations, as well as extensive intratumor heterogeneity in the pattern of structural changes but not in tumors with tumor-specific aberrations and low variability. Fluorescence in situ hybridization analysis demonstrated that chromosomes participating in anaphase bridge formation were involved in a significantly higher number of structural aberrations than other chromosomes. Tumors with BFB events showed a decreased elimination rate of unstable chromosome aberrations after irradiation compared with normal cells and other tumor cells. This result suggests that a combination of mitotically unstable chromosomes and an elevated tolerance to chromosomal damage leads to constant genomic reorganization in many malignancies, thereby providing a flexible genetic system for clonal evolution and progression.

Citing Articles

Breakage fusion bridge cycles drive high oncogene number with moderate intratumoural heterogeneity.

Dehkordi S, Wong I, Ni J, Luebeck J, Zhu K, Prasad G Nat Commun. 2025; 16(1):1497.

PMID: 39929823 PMC: 11811125. DOI: 10.1038/s41467-025-56670-8.


The interplay of the translocase activity and protein recruitment function of PICH in ultrafine anaphase bridge resolution and genomic stability.

Kong N, Chen K, Chanboonyasitt P, Jiang H, Wong K, Ma H Nucleic Acids Res. 2024; 53(3).

PMID: 39704103 PMC: 11797016. DOI: 10.1093/nar/gkae1249.


Exploring the potential of extrachromosomal DNA as a novel oncogenic driver.

Zhu H, Huangfu L, Chen J, Ji J, Xing X Sci China Life Sci. 2024; 68(1):144-157.

PMID: 39349791 DOI: 10.1007/s11427-024-2710-3.


CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma.

Saba K, Difilippo V, Styring E, Nilsson J, Magnusson L, van den Bos H NPJ Genom Med. 2024; 9(1):42.

PMID: 39322633 PMC: 11424644. DOI: 10.1038/s41525-024-00430-y.


Enhancer activation from transposable elements in extrachromosomal DNA.

Kraft K, Murphy S, Jones M, Shi Q, Bhargava-Shah A, Luong C bioRxiv. 2024; .

PMID: 39282372 PMC: 11398463. DOI: 10.1101/2024.09.04.611262.


References
1.
Schrock E, Du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith M . Multicolor spectral karyotyping of human chromosomes. Science. 1996; 273(5274):494-7. DOI: 10.1126/science.273.5274.494. View

2.
Bauknecht T, Schmidt J, Walz L, Pfleiderer A . Recurrent cytogenetic aberrations in human ovarian carcinomas. Cancer Detect Prev. 1995; 19(3):234-43. View

3.
Griffin C, Hruban R, Morsberger L, Ellingham T, Long P, Jaffee E . Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res. 1995; 55(11):2394-9. View

4.
Kastan M, Onyekwere O, Sidransky D, Vogelstein B, Craig R . Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51(23 Pt 1):6304-11. View

5.
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown J . Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282(5393):1497-501. DOI: 10.1126/science.282.5393.1497. View